Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.56 |
| ▸ | HTR6 | P50406 | 5/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.51 |
| ▸ | HTR3B | O95264 | 2/20 | 0.51 |
| ▸ | HTR3A | P46098 | 2/20 | 0.51 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.51 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR5A | P47898 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31349267 | 1.00 | ADRB1 (0.56) | ADRB1HTR6HTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL2322522 | 0.98 | ADRB1 (0.54) | ADRB1HTR6HTR3EHTR3BHTR3A | |
| SCHEMBL5707829 | 0.86 | ADRB1 (0.56) | ADRB1HTR6HTR3EHTR3BHTR3A | |
| SCHEMBL109882 | 0.84 | ADRB1 (0.55) | ADRB1HTR6HTR3EHTR3BHTR3A | |
| SCHEMBL5363288 | 0.84 | HTR6 (0.56) | ADRB1HTR6HTR3EHTR3BHTR3A | |
| SCHEMBL8251216 | 0.84 | ADRB1 (0.47) | ADRB1HTR6HTR3EHTR3BHTR3A | |
| SCHEMBL5373855 | 0.84 | HTR1A (0.60) | ADRB1HTR6HTR3EHTR3BHTR3A | |
| SCHEMBL15478265 | 0.84 | NPC1 (0.66) | LMNAMAPTTSHRHSD17B10NPC1 | |
| SCHEMBL1450313 | 0.83 | NPC1 (0.70) | ADRB1HTR6HTR3EHTR3BHTR3A | |
| SCHEMBL6966462 | 0.83 | ADRB1 (0.56) | ADRB1HTR6HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102304108-B | Five-membered heterocyclic dicarbonyl derivative and application thereof in resisting multidrug-resistant bacteria | UNIV CHINA PHARMA | 2013-11-06 | — | — | CN | disclosed |
| CN-103275041-A | Five-membered heterocyclic dicarbonyl derivative and applications thereof for resisting multidrug-resistant bacteria | UNIV CHINA PHARMA | 2013-09-04 | — | — | CN | disclosed |
| CN-102711734-A | Polymerizable lactamic copolymers suitable for the formation of coatings on microencapsulated particles | ISP INVESTMENTS INC | 2012-10-03 | — | — | CN | disclosed |
| CN-102304108-A | Five-membered heterocyclic dicarbonyl derivative and application thereof in resisting multidrug-resistant bacteria | UNIV CHINA PHARMA | 2012-01-04 | — | — | CN | disclosed |
| US-7488730-B2 | N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands | UNIVERSITA DEGLI STUDI DI BARI (IT) | 2009-02-10 | — | — | US | disclosed |
| US-20070117811-A1 | N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands | UNIVERSITA DEGLI STUDI DI BARI (IT) | 2007-05-24 | — | — | US | disclosed |
| US-7160888-B2 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT COMPANY LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| EP-1383772-B1 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MED CENTER (US) | 2006-08-30 | — | — | EP | disclosed |
| US-6825207-B2 | ANTICANCER AGENTS | CALIFORNIA PACIFIC MEDICAL CENTER | 2004-11-30 | — | — | US | disclosed |
| US-20040063740-A1 | For treatment of cancer | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2004-04-01 | — | — | US | disclosed |
| EP-1383772-A2 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | California Pacific Medical Center (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003101998-A1 | NITROGEN-BASED HOMO-CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-04-17 | — | — | US | disclosed |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-02-13 | — | — | US | disclosed |
| WO-2002070525-A2 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2002-09-12 | — | — | WO | disclosed |
| US-6403604-B1 | ANTITUMOR | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-06-11 | — | — | US | disclosed |
| US-6355642-B1 | PSYCHOLOGICAL DISORDERS AND BRAIN DISORDERS | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| EP-0937715-A1 | TETRAHYDROBENZINDOLE COMPOUNDS | MEIJI SEIKA KAISHA LTD. (JP) | 1999-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063740-A1 | For treatment of cancer | MGMT, PAICS, DCK | ADRB1 4165/4885HTR6 346/4885HTR3E 967/4885 |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | ADRB1 2878/4885HTR6 2180/4885HTR3E 2520/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | ADRB1 371/4885HTR6 789/4885HTR3E 1510/4885 |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | ADRB1 371/4885HTR6 789/4885HTR3E 1510/4885 |
| US-20070117811-A1 | N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands | HTR7, HTR3A, HTR1E | ADRB1 100/4885HTR6 12/4885HTR3E 7/4885 |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | ADRB1 2878/4885HTR6 2180/4885HTR3E 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.